Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Disorders of Leukocytes01:27

Disorders of Leukocytes

Leukocyte disorders can lead to either leukopenia, characterized by an abnormally low leukocyte count, or leukocytosis, marked by a very high leukocyte number.
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune system...
Structure and Function of Leukocytes01:21

Structure and Function of Leukocytes

An adult in good health typically has between 4,500 and 11,000 leukocytes, or white blood cells, per microliter of blood, which constitutes about 1% of the total blood volume. Unlike red blood cells, white blood cells contain a nucleus and other cellular organelles but do not have hemoglobin. Most white blood cells reside in connective tissues, particularly in lymphatic organs such as the lymph nodes, with only a small fraction present in circulating blood.
White blood cells protect the body...
Differentiation of Common Myeloid Progenitor Cells01:15

Differentiation of Common Myeloid Progenitor Cells

Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Alemtuzumab in combination with methylprednisolone is a highly effective induction regimen for patients with chronic lymphocytic leukemia and deletion of TP53: final results of the national cancer research institute CLL206 trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2012
Same author

Searching for surrogates for IGHV mutations in chronic lymphocytic leukemia.

Leukemia research·2011
Same author

The Myelodysplastic Syndromes (MDS) Foundation: a retrospective analysis of a nonprofit foundation.

Leukemia research·2010
Same author

The TCL1 mouse as a model for chronic lymphocytic leukemia.

Leukemia research·2009
Same author

Fludarabine, cyclophosphamide and rituximab for chronic lymphocytic leukemia: no country for old men?

Nature clinical practice. Oncology·2009
Same author

Complementary medicine . Inconsistency over payment.

BMJ (Clinical research ed.)·2008
Same journal

A multicenter real-world study of clinical outcomes in octogenarians and older patients with acute myeloid leukemia.

Leukemia research·2026
Same journal

FLAMSA versus FLAG-IDA as salvage therapy in adults with relapsed/refractory acute myeloid leukemia and acute lymphoblastic leukemia: A single-center real-world retrospective study.

Leukemia research·2026
Same journal

CD244 modulates bone marrow infiltrating CD8<sup>+</sup> T cells and serves as a prognostic and immunotherapeutic target in acute myeloid leukemia.

Leukemia research·2026
Same journal

Long-term remission and survival in older adults with IDH-mutated acute myeloid leukemia treated with IDH inhibitors.

Leukemia research·2026
Same journal

Real-world outcomes of plasmablastic lymphoma: Treatment approaches and survival outcomes in the PLASMABLAT-001 cohort.

Leukemia research·2026
Same journal

CRS and ICANS as class-level adverse event for CD20 ×CD3 bispecific T-cell engagers: A Bayesian analysis of a nationwide database.

Leukemia research·2026
See all related articles

Related Experiment Video

Updated: Jun 21, 2026

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation
09:02

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation

Published on: November 26, 2018

Just exactly how common is CLL?

Terry J Hamblin

    Leukemia Research
    |July 28, 2009
    PubMed
    Summary

    No abstract available in PubMed .

    More Related Videos

    Subcellular Fractionation of Primary Chronic Lymphocytic Leukemia Cells to Monitor Nuclear/Cytoplasmic Protein Trafficking
    11:39

    Subcellular Fractionation of Primary Chronic Lymphocytic Leukemia Cells to Monitor Nuclear/Cytoplasmic Protein Trafficking

    Published on: October 23, 2019

    From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia
    10:18

    From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia

    Published on: October 19, 2014

    Related Experiment Videos

    Last Updated: Jun 21, 2026

    Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation
    09:02

    Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation

    Published on: November 26, 2018

    Subcellular Fractionation of Primary Chronic Lymphocytic Leukemia Cells to Monitor Nuclear/Cytoplasmic Protein Trafficking
    11:39

    Subcellular Fractionation of Primary Chronic Lymphocytic Leukemia Cells to Monitor Nuclear/Cytoplasmic Protein Trafficking

    Published on: October 23, 2019

    From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia
    10:18

    From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia

    Published on: October 19, 2014